Safety unanimous, benefit split
Pause on the split. An advisory panel accepted the safety of Grail's Galleri blood test 10-0. Effectiveness stayed 6 in favour to 4 against. Whether benefits outweigh risks drew 7 in favour, 2 against and 1 abstention.[1]
The panel is not an approval. No multi-cancer early detection test has FDA approval yet. Goel called the vote an encouraging step rather than the final word on clinical value.[1]
287 signals and a negative result
The test is designed for people 50 and over. A negative result does not rule cancer out. Goel called the vote an encouraging step rather than the final word on clinical value.[1]
The uncertainty carried at 50
The test is designed for people 50 and over. A unanimous safety vote does not close the 6-4 split on effectiveness. The final word on clinical value is not yet in place, and this step does not yet place a screen for people 50 and over.[1]